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CRITICAL CARE
High-Grade Nucleoside Transport Inhibition Stimulates Ventilation in Humans
Gerard A. Rongen, MD, Paul Smits, MD, PhD, Gorben Bootsma, MD, Kris Ver Donck, PhD,
Albrecht de Vries, MSc, and Theo Thien, MD, PhD
In 6 healthy male volunteers a placebo-controlled, double-blind, random ized , crossover 
trial was done to assess the ejject of 1, 2 , 4, and  6 mg o/ draflazine, a  specific nucleoside 
transport inhibitor, on ventilation. Draflazine increased thoracic excursions dose-depen- 
den tly by m axim ally  (median with 95% confidence interval) 114.0% (38.3-184.8%) with­
out affecting breathing rate. Ex vivo adenosine transport was inh ib ited  by 0% (0 -1% )  
after placebo, and  70% (59-74%), 81% (76-85%), 90% (86-93% ), and 93%  (90-96% ) after 
the 4 increasing draflazine dosages, respectively (P <  ,05 for each draflazine dosage ver­
sus placebo]. These results indicate that endogenously released ad en o sin e  m a y  p lay  a role 
in the regulation of ventilation.
Intravenous injection of adenosine has been re­ported to stimulate ventilation in humans.1”4 The 
adenosine receptor antagonist theophylline does not reduce ventilation in healthy volunteers,5 suggesting that endogenous adenosine does not play an impor­tant role in the regulation of ventilation. However, theophylline crosses the blood-brain barrier, and the contrasting central and peripheral effects of adeno­sine may offer an explanation for the lack of effect of theophylline on ventilation.6 Alternatively, the physiologic importance of adenosine can be evalu­ated by inhibiting its cellular uptake. Although di­pyridamole augmented the ventilatory effects of in­travenously injected adenosine,7,8 it did not affect ventilation during isocapneic hypoxia when given orally.5 In contrast, it has recently been reported that intravenously injected dipyridamole stimulates ven­tilation in humans.9 Besides the variable oral avail-
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ability of dipyridamole,10 nonspecific actions such as phosphodiesterase inhibition and stimulation of prostacyclin release11,12 may have interfered, possi­bly accounting for these contrasting results. Based on these previous observations, we hypothesized that endogenously released adenosine is able to stimulate ventilation in humans. To test this hypothesis, we decided to study the effect of intravenously injected draflazine, a specific nucleoside transport inhibitor, on ventilation. Draflazine, the active (—)-enantiomer of R 75 231, has a tight binding to the nucleoside transporter.13 Phase I studies in humans reveal a long duration of action: 50% ex vivo adenosine transport inhibition at 4 hours after a total dose of 10 mg of R 75 231 (resembling 5 mg draflazine) intravenously.14 The advantage of using draflazine instead of dipyri­damole is that draflazine does not possess nonspecific confounding effects as does dipyridamole. Drug effectivity was monitored by measuring ex vivo nu­cleoside transport inhibition.
SUBJECTS AND METHODS 
Subjects
After approval of the local ethics committee, 6 nor- motensive, nonsmoking, healthy, Caucasian, non- obese, male volunteers [age: 44 (29-53) years; height:
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180 (172-189] cm] signed written informed consent before participation. They had no history of pulmo­nary disease and did not use concomitant medica­tion.
Study Design
The ventilatory effects of placebo and 1, 2, 4, or 6 mg of draflazine were studied during 5 sessions per vol­unteer, that were separated by at least 1 week. The administration of placebo or draflazine was random­ized and double-blind, except for the highest dose (6 mg). The 6-mg dose was always given in the final ses­sion in a single-blind way for safety reasons, because at the time of these experiments this dosage had not been given before. Each experiment was done in the morning after a 24-hour abstinence from caffeine- containing products and an overnight fast of at least 10 hours. Both arms were intravenously cannulated to infuse the drug (left arm] and to collect blood (right arm]. Immediately before and after the 15-minute drug infusion, blood was collected for measurement of plasma adenosine15 and ex vivo nucleoside transport.16 Ventilation was measured by registra­tion of each thoracic excursion that occurred during three minutes before the start of draflazine infusion (baseline period) and immediately after draflazine administration*4
Measurement of Ventilation
Thoracic excursions were measured using mercury- in-Silastic strain gauge plethysmography (Hokanson EC4, D,E. Hokanson, Inc.; Washington, DC). A 26-cm mercury-in-Silastic strain gauge was wrapped around the thorax at the midsternal level. To bridge the remaining gap, both ends of the Silastic tube were attached to an unextensible band at the back of the volunteer. As the thorax expands, the length of the gauge is changed by a corresponding amount. The re­sulting variations in the voltage drop across the gauge will reflect changes in thoracic circumference. In a separate group of 6 healthy nonobese male vol­unteers [age: 29 (22-36) years; height: 180 (172-190) cm], this method was validated against simultaneous spirometric recordings (Figure 1). Although confi­dence intervals were considerably higher for the pie- thysmographic technique, an increase in tidal vol­ume as recorded by spirometry almost always ac­companied an increase in thoracic excursion for each individual.
Analytical Methods
To measure plasma adenosine concentration, 2 mL of blood was collected and directly mixed during col-
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Figure 1. Six subjects were asked to breath with a Udal volume of 
approximately 600 (baseline), 800, 1000, 1200, 1400, and 1600 mL. 
They adjust their ventilation by watching a continuous registration 
of their tidal volume by spirometry. Changes in real tidal volume 
(spirometry) and thoracic excursions (strain gauge plethysmogra­
phy] were expressed as percentage change from baseline.
The upper panel shows the group average changes in thoracic 
excursion (plethysmography) in comparison with changes in tidal 
volume (spirometry) expressed as median with 95%  confidence in­
terval. The lower panel shows individual changes in these two pa­
rameters.
lection with 2 mL of “blocker solution” using a spe­cially designed device. The blocker solution con­tained the adenosine deaminase inhibitor erythro- 9(2-hydroxy-3-nonyl)-adenosine (EHNA, 10 nm ol/  L), the adenosine transport inhibitor dipyridamole
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(20 jumol/L), and the thrombocyte aggregation inhib­itor indomethacin (2 mg/L). Immediately after blood collection, the blood/blocker mixture was centri­fuged (Eppendorf centrifuge, Model 3200; Eppen- dorf-Netheler-Hinz Gmbh, Hamburg, Germany,] at 3000 rpm for 2 minutes, and the plasma was depro- teinated with perchloric acid as previously de­scribed.15 The extract was kept frozen at —20°C until the adenosine concentration was determined in duplo by reversed-phase high-performance liquid chromatography using a nonlinear gradient. This adenosine determination has an intra-assay coeffi­cient of variation of 16.2 ± 2.2% (11 subjects, in each 
subject 5 duplo determinations) and an intra-indi- vidual coefficient of variation of 20.7 ± 7.2% (11 sub­jects, 4 samples in each subject).
Ex vivo adenosine transport inhibition was mea­sured by standardized incubation of erythrocytes with adenosine. Four milliliters of blood was drawn into a vial containing 1 mL of citrate/acid/dextrose (85 /xmol/L of trisodium citrate, 65 ¿¿mol/L of citric acid, and 20 g/L of glucose) and further handled as previously described.16 The percentage of adenosine transport inhibition (ATI%) was calculated as fol­lows:
ATI% = (Ax -  Ao) X 100/(1 -  A0)
in which A0 represents the adenosine concentration as a proportion of the sum of the concentration of adenosine, inosine, and hypoxanthine as determined in the sample collected just before the drug infusion; and Ax represents this proportion as determined in the sample collected after the start of the drug infu­sion.
Drugs and Solutions
Draflazine or placebo solutions in a formulation with 5% hydroxypropyl-/?-cyclodextrine (Janssen Phar- maceutica; Beerse, Belgium) were prepared with so­dium chloride (NaCl 0.9%) by a specially trained re­search nurse who was not otherwise involved in the 
practical performance of the trial.
Statistics
For each three-minute registration period, the tho­racic excursions were averaged to one value. Effects of placebo or drug infusion were expressed as per­centage change from baseline. When an overall anal­ysis by Friedman two-way nonparametric analysis of variance (ANOVA) showed significant differences in responses (P < .05, chi-square test), the paired Wil- coxon signed rank test was used to find out which
draflazine dosages were different from placebo. All results are expressed as median (95% confidence in­terval).
RESULTS
Figure 2 shows the effect of draflazine on breathing rate and tidal volume. Draflazine did not signifi­cantly affect breathing rate. Tidal volume changed by —7,2%  (—36.5-49.1%) after placebo, and —8.7% (-35.4-47.8%), 38.4% (0.0-121.3%), 35.0% (-10.5- 70.4%), and 114.0% (38.3-184.8%) after 1, 2, 4, and 6 mg of draflazine, respectively (P < .05 versus placebo for 2, 4, and 6 mg of draflazine]. Nucleoside transport was inhibited by 0% (0-1%) after placebo, and 70% (59-74%), 81% (76-85%), 90% (86-93%), and 93% (90-96%) after the 4 increasing draflazine dosages, respectively (P < .05 for each draflazine dosage ver­sus placebo). Plasma adenosine concentrations did not significantly change: 0.0 ¿¿mol/L (—0.06-0.03 /¿mol/L) after placebo, and 0.0 ¿¿mol/L (—0.02-0.0 ¿¿mol/L), 0,02 ¡xmol/L (0.0-0.11 ¿¿mol/L), 0.02 /¿mol/ L (0.0-0.11 ^inol/L}, and 0.0 ¿imol/L (—0.06-0.06 /¿mol/L) after 1, 2, 4, and 6 mg of draflazine (Fried­
man: P ~ .12).
DISCUSSION
These results show that ventilation is increased by high-grade nucleoside transport inhibition with draflazine. Until now, nucleoside transport inhibi­tion has been the only known action of this drug.13,17~19 Recently, we have shown that the hemodynamic and neurohumoral effects of high-grade nucleoside transport inhibition with draflazine in humans can be antagonized with the adenosine receptor antago­nist caffeine.20 This supports the assumption that the effects of draflazine are mediated by endogenous adenosine. Additionally, draflazine is able to poten­tiate the vasodilator effect of intra-arterially-infused adenosine in humans21 confirming the in vivo action of draflazine as a nucleoside transport inhibitor. Therefore, the present results suggest that endoge­nously released adenosine can play a role in the reg­ulation of ventilation. Plasma adenosine concentra­tion was not significantly affected by draflazine. This finding contrasts with the observations of others22,23 who reported a doubling of adenosine concentrations after dipyridamole administration.22,23 However, in these dipyridamole studies adenosine formation, up­take, and breakdown after blood sampling were not optimally antagonized. Therefore, in these studies baseline plasma adenosine concentrations may have been underestimated, and the administered dipyri­damole may have affected adenosine uptake by
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Figure 2. EffecLs of placebo (0 mg], 1, 2, 4, and 6 mg of draflazine 
on plefhysmographically determined tidai volume (upper panel), 
breaihing rate (middle panel), and ex vivo nucleoside transport 
inhibition (NTI, lower panel) as deiermined by standardized incu­
bation of erythrocytes with adenosine are shown. Results are ex­
pressed as median with 95% confidence interval. * indicates statis­
tically significant differences from placebo.
erythrocytes after blood sampling. The present study does not rule out a small draflazine-induced increase in plasma adenosine levels, because intra-sub}ect variability of the adenosine detection method is
high. Additionally, we cannot exclude a detectable increase in adenosine concentration during more sustained nucleoside transport inhibition. Alterna­tively, nucleoside transport inhibition may trans­form the endothelium to a functional barrier pre­venting adenosine from leaving the interstitial space and resulting in an increase of adenosine in the in­terstitial compartment only.In conclusion, draflazine-induced high-grade nu­
cleoside transport inhibition stimulates ventilation in humans. We suggest that this effect is mediated by an increased extracellular adenosine concentration in the interstitial compartment only.
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